$0.24
-0.01(-2.76%)
Mkt Cap $2M
$0.12
$1.27
52-Week Range
At a Glance
AI-generatedFY2025 delivered sharply wider operating and net losses of -$25.5M and -$25.0M respectively, driven by a significant IPR&D impairment from sustained market capitalization decline, amid ongoing clinical development and acute month-to-month liquidity constraints.
8-K
ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement on February 27, 2026, issuing $1 million in convertible promissory notes and Series A-4 Common Stock Purchase Warrants to accredited investors in a private placement, with net proceeds for working capital.$2M
Market Cap
—
Revenue
—
Net Income
Employees7
Fundamentals
How The Business Makes Money
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001859007
ISINUS98987D2018
CUSIP98987D201
Phone754 231 1688
Address2200 N. Commerce Parkway, Weston, FL, 33326, US
SEC EDGAR